Contineum Therapeutics (CTNM) Payables (2023 - 2026)

Contineum Therapeutics' Payables history runs 4 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• On a quarterly basis, Payables fell 58.98% year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was $1.5 million, a 58.98% decrease from a year earlier, with the FY2025 full-year figure at $1.0 million, down 43.9% from the prior year.
• Payables advanced to $1.5 million in Q1 2026 per CTNM's latest filing, from $1.0 million in the prior quarter.
• Across five years, Payables topped out at $3.6 million in Q1 2025 and bottomed at $570000.0 in Q1 2024.
• The 4-year median for Payables is $1.2 million (2024), against an average of $1.4 million.
• Across the five-year window, Payables jumped 539.47% in 2025 and slumped 58.98% in 2026, its largest moves.
• Year by year, Payables stood at $635000.0 in 2023, then jumped by 185.2% to $1.8 million in 2024, then tumbled by 43.9% to $1.0 million in 2025, then soared by 47.15% to $1.5 million in 2026.
• Per Business Quant, the three latest CTNM Payables figures stand at $1.5 million (Q1 2026), $1.0 million (Q4 2025), and $786000.0 (Q3 2025).